VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · Real-Time Price · USD
0.590
-0.005 (-0.82%)
Mar 9, 2026, 4:00 PM EDT - Market closed
VYNE Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Mar '26 Mar 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 20 | 19 | 49 | 33 | 9 | 55 | |
| Market Cap Growth | -50.62% | -60.93% | 51.96% | 273.57% | -84.05% | -79.42% | |
| Enterprise Value | -9 | -13 | -21 | 17 | -27 | 3 | |
| Last Close Price | 0.59 | 0.58 | 3.35 | 2.33 | 2.70 | 18.36 | |
| PS Ratio | 34.50 | 33.88 | 98.64 | 76.70 | 18.25 | 58.63 | |
| PB Ratio | 0.71 | 0.70 | 0.95 | 0.37 | 0.28 | 1.12 | |
| P/TBV Ratio | 0.71 | 0.70 | 0.95 | 0.37 | 0.28 | 1.12 | |
| EV/Sales Ratio | - | - | - | 40.27 | - | 3.58 | |
| Debt / Equity Ratio | - | - | 0.00 | 0.00 | - | 0.01 | |
| Net Debt / Equity Ratio | -1.04 | -1.04 | -1.18 | -1.05 | -0.98 | -0.86 | |
| Net Debt / EBITDA Ratio | 0.98 | 0.98 | 1.41 | 3.19 | 0.90 | 1.08 | |
| Net Debt / FCF Ratio | 0.88 | 0.88 | 1.80 | 3.67 | 1.06 | 0.74 | |
| Asset Turnover | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Quick Ratio | 12.11 | 12.11 | 4.15 | 12.37 | 3.84 | 2.71 | |
| Current Ratio | 12.53 | 12.53 | 4.35 | 12.73 | 4.10 | 3.43 | |
| Return on Equity (ROE) | -66.97% | -66.97% | -56.54% | -46.40% | -84.81% | -102.66% | |
| Return on Assets (ROA) | -38.31% | -38.31% | -33.14% | -26.42% | -39.77% | -30.25% | |
| Return on Capital Employed (ROCE) | -107.10% | -107.10% | -83.80% | -32.50% | -109.20% | -80.00% | |
| Earnings Yield | -134.65% | -137.15% | -80.61% | -87.49% | -266.62% | -134.33% | |
| FCF Yield | -168.42% | -171.54% | -68.98% | -77.92% | -335.43% | -103.26% | |
| Buyback Yield / Dilution | -0.42% | -0.42% | -314.57% | -222.44% | -11.44% | -58.75% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.